Novel peptides or peptidomimetic agents or small molecules for modulating the biological effect of a chemokine. According to the present invention, the therapeutic agents preferably are endowed with the capacity to bind to certain chemokines in order to modulate the biological interaction between the target ligand, chemokine, and the respective target receptor, chemokinereceptor. These peptides may be described as agonist ligands or antagonists. Next, preferably certain peptides share consensus sequences are described which characterize the families or categories of these modulator peptides.
A novel CC-chemokinebinding protein is isolated from the saliva of Rhipicephalus sanguineus. Compounds prepared in accordance with the present invention can be used as anti-inflammatory compounds and in the treatment or prevention of CC-chemokine-related diseases.
A novel CC-chemokinebinding protein is isolated from the saliva of Rhipicephalus sanguineus. Compounds prepared in accordance with the present invention can be used as anti-inflammatory compounds and in the treatment or prevention of CC-chemokine-related diseases.
The invention provides application of a compound in preparing an anti-mammary cancer medicament aiming at CCL (CC chemokine ligand)18 target. The compound is glycinate with protection radical and can be used as the anti-mammary cancer medicament aiming at the CCL18 target. The structural formula of the compound is shown as formula I. The invention also provides an anti-mammary cancer medicament, wherein the medicament contains effective dose of a compound with a structural formula shown in the formula I. The invention provides the application of the glycinate compound with protection radical shown as the formula I aiming at the CCL18 target in preparing the anti-mammary cancer medicament, and provides a new medicament for treating the mammary cancer.